Table 1.
Characteristics of the liposarcoma with distant metastasis at diagnosis in the SEER dataset from 2010 to 2016
| Characteristics | Total distant metastasis | Metastasis | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|||||||||
| Not | % | Yes | % | χ2 | P-value | Lung | Liver | Bone | Brain | |
| Sex | 1.48 | 0.224 | ||||||||
| Male | 2,312 | 94.21% | 142 | 5.79% | 58 | 26 | 28 | 5 | ||
| Female | 1,642 | 95.08% | 85 | 4.92% | 29 | 25 | 22 | 2 | ||
| Age (year) | 4.49 | 0.034 | ||||||||
| <60 | 1,993 | 95.31% | 98 | 4.69% | 39 | 19 | 28 | 3 | ||
| ≥60 | 1,961 | 93.83% | 129 | 6.17% | 48 | 32 | 22 | 4 | ||
| Race | 3.86 | 0.425 | ||||||||
| White | 3,137 | 94.49% | 183 | 5.51% | 70 | 36 | 43 | 4 | ||
| Black | 360 | 94.49% | 21 | 5.51% | 9 | 5 | 2 | 2 | ||
| IA | 35 | 97.22% | 1 | 2.78% | 0 | 1 | 0 | 0 | ||
| API | 365 | 94.32% | 22 | 5.68% | 8 | 9 | 5 | 1 | ||
| Unknown | 57 | 100.00% | 0 | 0.00% | 0 | 0 | 0 | 0 | ||
| Insurance recode | 6.95 | 0.031 | ||||||||
| Insured | 3,737 | 94.70% | 209 | 5.30% | 81 | 46 | 44 | 5 | ||
| Uninsured | 121 | 89.63% | 14 | 10.37% | 6 | 5 | 5 | 2 | ||
| Unknown | 96 | 96.00% | 4 | 4.00% | 0 | 0 | 1 | 0 | ||
| Marital status | 5.06 | 0.080 | ||||||||
| Married | 2,320 | 94.89% | 125 | 5.11% | 45 | 26 | 26 | 2 | ||
| Unmarried | 1,375 | 93.66% | 93 | 6.34% | 39 | 22 | 22 | 5 | ||
| Unknown | 259 | 96.64% | 9 | 3.36% | 3 | 3 | 2 | 0 | ||
| Year of diagnosis | 10.99 | 0.089 | ||||||||
| 2010 | 492 | 96.09% | 20 | 3.91% | 9 | 3 | 2 | 1 | ||
| 2011 | 538 | 96.24% | 21 | 3.76% | 9 | 9 | 5 | 0 | ||
| 2012 | 551 | 93.71% | 37 | 6.29% | 9 | 4 | 9 | 0 | ||
| 2013 | 540 | 94.74% | 30 | 5.26% | 11 | 5 | 6 | 1 | ||
| 2014 | 598 | 94.62% | 34 | 5.38% | 17 | 7 | 12 | 2 | ||
| 2015 | 587 | 94.52% | 34 | 5.48% | 13 | 6 | 8 | 3 | ||
| 2016 | 648 | 92.70% | 51 | 7.30% | 19 | 17 | 8 | 0 | ||
| Primary site | 46.42 | <0.001 | ||||||||
| Extremities | 1,846 | 96.75% | 62 | 3.25% | 24 | 10 | 20 | 0 | ||
| Trunk | 1,192 | 93.05% | 89 | 6.95% | 36 | 17 | 17 | 3 | ||
| RIA | 831 | 93.16% | 61 | 6.84% | 17 | 20 | 5 | 2 | ||
| Thorax | 26 | 89.66% | 3 | 10.34% | 2 | 0 | 2 | 1 | ||
| Others | 59 | 83.10% | 12 | 16.90% | 8 | 4 | 6 | 1 | ||
| Histology | 91.08 | <0.001 | ||||||||
| Well-differentiated | 1,453 | 98.58% | 21 | 1.42% | 7 | 5 | 4 | 1 | ||
| De-differentiated | 795 | 89.73% | 91 | 10.27% | 35 | 16 | 11 | 0 | ||
| Myxoid | 828 | 94.20% | 51 | 5.80% | 14 | 10 | 16 | 2 | ||
| Pleomorphic | 257 | 92.11% | 22 | 7.89% | 13 | 4 | 5 | 2 | ||
| Others | 113 | 93.39% | 8 | 6.61% | 3 | 3 | 3 | 0 | ||
| Unknown | 508 | 93.73% | 34 | 6.27% | 15 | 13 | 11 | 2 | ||
| Grade | 145.87 | <0.001 | ||||||||
| Grade I | 1,894 | 98.54% | 28 | 1.46% | 12 | 7 | 5 | 3 | ||
| Grade II | 518 | 95.22% | 26 | 4.78% | 2 | 4 | 9 | 0 | ||
| Grade III | 556 | 92.67% | 44 | 7.33% | 10 | 14 | 11 | 0 | ||
| Grade IV | 496 | 88.10% | 67 | 11.90% | 33 | 9 | 10 | 2 | ||
| Unknown | 490 | 88.77% | 62 | 11.23% | 30 | 17 | 15 | 2 | ||
| T stage | 52.29 | <0.001 | ||||||||
| T1 | 427 | 97.49% | 11 | 2.51% | 3 | 2 | 2 | 0 | ||
| T2 | 3,263 | 94.97% | 173 | 5.03% | 66 | 37 | 36 | 3 | ||
| Unknown | 264 | 85.99% | 43 | 14.01% | 18 | 12 | 12 | 4 | ||
| N stage | 197.65 | <0.001 | ||||||||
| N0 | 3,772 | 95.66% | 171 | 4.34% | 58 | 38 | 35 | 4 | ||
| N1 | 41 | 62.12% | 25 | 37.88% | 10 | 9 | 9 | 1 | ||
| Unknown | 141 | 81.98% | 31 | 18.02% | 19 | 4 | 6 | 2 | ||
| Number of Met | 650.24 | <0.001 | ||||||||
| ≤1 | 3954 | 95.42% | 190 | 4.58% | 55 | 30 | 26 | 3 | ||
| >1 | 0 | 0 | 37 | 100% | 32 | 21 | 24 | 4 | ||
| Vital status | 362.70 | <0.001 | ||||||||
| Alive | 3,292 | 97.86% | 72 | 2.14% | 20 | 15 | 10 | 0 | ||
| Dead | 662 | 81.03% | 155 | 18.97% | 67 | 36 | 40 | 7 | ||
| Surg (prim) | 402.17 | <0.001 | ||||||||
| None | 280 | 72.54% | 106 | 27.46% | 57 | 26 | 24 | 5 | ||
| Yes | 3,667 | 96.81% | 121 | 3.19% | 30 | 25 | 26 | 2 | ||
| Unknown | 7 | 100.00% | 0 | 0.00% | 0 | 0 | 0 | 0 | ||
Abbreviations: SEER: Surveillance, Epidemiology, and End Result; Met = Metastases. RIA: Retroperitoneal/intra-abdominal; IA: Indian/Alaska Native; API: Asian or Pacific Islander; Surg (prim): surgery for primary tumor.